Figure 1.
Cumulative probability of remaining on anti-tumour necrosis factor [TNF] therapy from time of anti-TNF monotherapy initiation in the 297 patients not needing an immunomodulator during follow-up.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.